Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study.

@article{Stokman2004OutcomeOL,
  title={Outcome of local application of amifostine (WR-1065) on epirubicin-induced oral mucositis. A phase II study.},
  author={Monique A. Stokman and Floris M. Wachters and Peter P. Koopmans and J. G. M. Burgerhof and Harry J. M. Groen and Frederik K. L. Spijkervet and Donald R. A. Uges and Geke A. P. Hospers},
  journal={Anticancer research},
  year={2004},
  volume={24 5B},
  pages={3263-7}
}
BACKGROUND Intravenous administration of amifostine reduces chemotherapy-induced toxicity. Preclinical experiments showed a reduction in radiation-induced mucositis after local application of the active metabolite of amifostine (WR-1065). This study evaluated the effect of local application of WR-1065 on chemotherapy-induced oral mucositis. PATIENTS AND METHODS Non-small cell lung cancer patients treated with gemcitabine and epirubicin every 3 weeks for a maximum of five cycles were included… CONTINUE READING